Warnings Benzyl Alcohol: Patients who have early Leber's disease (LHON) a hereditary disease that causes optic nerve atrophy have been found to suffer severe and swift optic atrophy when treated with vitamin B12
90480 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose (for all ages) 91318 (Pfizer) Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (6 months through 4 years) 91319 (Pfizer) Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (5 years through 11 years) 91320 (Pfizer) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (12 years and older) 91321 (Moderna) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use (6 months through 11 years) 91322 (Moderna) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use (12 years and older) Respiratory Syncytial Virus (RSV) Vaccine CPT Codes Adults 65 and over and adults with chronic conditions or weakened immune systems are at high risk for developing severe RSV
These materials are not therapeutic goods and have not been evaluated by the Therapeutic Goods Administration (TGA)
Tirzepatide exposure increases in a dose-proportional manner
